Icatibanto Exeltis

Icatibant, the active ingredient in Icatibanto Exeltis, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with confirmed diagnosis.

GNH USA supplies Icatibanto Exeltis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Clients benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

- Acute attacks of hereditary angioedema: rapid reduction of swelling, pain and associated airway obstruction.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional upset stomach. - Headache: mild to moderate. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or urticaria. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Angioedema unrelated to HAE: swelling of face, lips, or tongue. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count.

Before initiating therapy, clinicians should consider several safety measures.

- Patient history review: assess for prior hypersensitivity to icatibant or excipients. - Monitor for allergic reactions: observe for signs of rash, urticaria, or anaphylaxis after injection. - Contraindication check: avoid in patients with known B2‑receptor deficiency. - Caution in organ impairment: adjust monitoring in renal or hepatic dysfunction. - Patient education: instruct on proper subcutaneous technique and self‑administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate angioedema. - Neprilysin inhibitors: elevate bradykinin and risk of severe edema. - Direct B2‑receptor agonists: antagonistic effect reduces therapeutic benefit.

Moderate Interactions (Monitor Closely): - Estrogen‑containing therapies: may potentiate hereditary angioedema severity. - Other vasoactive peptides: monitor blood pressure and vascular responses. - Antihistamines: may mask early signs of hypersensitivity, requiring vigilant observation.